MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders. Its primary focus is on discovering and advancing circuit-specific treatments designed to address severe and difficult-to-treat brain conditions such as schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, and Parkinson’s disease. The company's leading drug candidate, ML-007C-MA, combines M1/M4 muscarinic agonism with a peripherally acting anticholinergic, specifically targeting symptoms of schizophrenia and Alzheimer’s disease-related psychosis. Additional candidates in the pipeline address social deficits in autism, motor issues in Parkinson’s disease, and agitation-related disorders through novel pharmacological approaches. Founded in 2018 by leaders in psychiatry and neuroscience, MapLight Therapeutics leverages a proprietary discovery platform that identifies and modulates neural circuits causally linked to disease, aiming to move beyond the limitations of traditional CNS medications. The company plays a significant role in the ongoing evolution of neuropsychiatric drug development, prioritizing scientific rigor and circuit specificity to potentially offer safer and more effective therapeutic options for underserved patient populations.